title: Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.
abstract: BACKGROUND
  Major bleeding during an acute coronary syndrome (ACS) is associated with increased late ischemic events. Patients with bleeding are often discharged without antiplatelet therapy (AT). The association between discharge AT use and late ischemic outcomes among ACS patients with bleeding is uncertain.
  
  
  METHODS
  We examined discharge AT use among 8,582 ACS patients with in-hospital bleeding from a total of 26,451 patients enrolled in 4 randomized trials. After adjusting for the propensity to receive AT, we compared 6-month postdischarge outcomes between patients discharged with and those discharged without AT.
  
  
  RESULTS
  Almost 1 in 10 patients with bleeding was discharged without AT (n=826). Compared with those receiving discharge AT, those not receiving discharge AT had a higher risk of 6-month death, myocardial infarction, and stroke (14.3% vs 7.8%, propensity-adjusted hazard ratio [HR]=1.36, 95% confidence interval=1.01-1.85). Nonuse of AT at discharge was associated with worse outcomes among patients treated with percutaneous coronary intervention compared with those treated without it (adjusted HR=4.22 vs 1.13, interaction P=.0003). Discharge monotherapy was associated with worse outcomes than dual AT among patients receiving stents (adjusted HR=1.78, 95% CI=1.04-3.03).
  
  
  CONCLUSIONS
  Bleeding occurred commonly among patients with ACS. AT was often not used in these patients at discharge, and lack of discharge AT was associated with an increased risk of 6-month ischemic events. These data raise the possibility that lack of AT use among patients with in-hospital bleeding may contribute to their excess risk of long-term ischemic outcomes.
authors.affiliation: National University Heart Centre, Singapore, Singapore. mark_chan@nuhs.edu.sg
authors.forename: Mark Y
authors.initials: MY
authors.lastname: Chan
authors.forename: Jie L
authors.initials: JL
authors.lastname: Sun
authors.forename: Tracy Y
authors.initials: TY
authors.lastname: Wang
authors.forename: Renato D
authors.initials: RD
authors.lastname: Lopes
authors.forename: Marc E
authors.initials: ME
authors.lastname: Jolicoeur
authors.forename: Karen S
authors.initials: KS
authors.lastname: Pieper
authors.forename: Sunil V
authors.initials: SV
authors.lastname: Rao
authors.forename: L Kristin
authors.initials: LK
authors.lastname: Newby
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Mahaffey
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harrington
authors.forename: Eric D
authors.initials: ED
authors.lastname: Peterson
mesh_terms: D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010351:Patient Discharge; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D010975:Platelet Aggregation Inhibitors